A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

Clinical trial NCT06253130 · RECRUITING

Trial details

NCT number: NCT06253130
Sponsor: Eikon Therapeutics
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Solid Tumor

Start date: 2023-12-11
Primary completion: 2027-06-01
Enrollment: 156

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.